Ageing and Dementia Current and Future Concepts

Front Matter....Pages I-VIII
Vascular-ischemic dementia: an update....Pages 1-23
Frequency of white matter lesions and silent lacunar infarcts....Pages 25-39
CT and MRI rating of white matter changes....Pages 41-45
Risk factors and progression of small vessel disease-related cerebral abnormalities....Pages 47-52
Microangiopathy-related cerebral damage and angiotensinogen gene: from epidemiology to biology....Pages 53-59
Can small-vessel disease-related cerebral abnormalities be used as a surrogate marker for vascular dementia trials?....Pages 61-67
Reactive oxygen: its sources and significance in Alzheimer disease....Pages 69-75
Dysregulation of neuronal differentiation and cell cycle control in Alzheimer’s disease....Pages 77-85
A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?....Pages 87-95
Is mild cognitive impairment bridging the gap between normal aging and Alzheimer’s disease?....Pages 97-104
Vienna Transdanube Aging “VITA”: study design, recruitment strategies and level of participation....Pages 105-116
Conversion from preclinical to clinical stage of Alzheimer’s disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation....Pages 117-125
The role of biological markers in the early and differential diagnosis of Alzheimer’s disease....Pages 127-133
Measuring cognition in advanced Alzheimer’s disease for clinical trials....Pages 135-148
Current drugs and future hopes in the treatment of Alzheimer’s disease....Pages 149-164
Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library....Pages 165-179
Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease....Pages 181-187
Impact of muscarinic agonists for successful therapy of Alzheimer’s disease....Pages 189-202
Nicotinic receptor modulation: Advantages for successful Alzheimer’s disease therapy....Pages 203-216
Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?....Pages 217-225
Can estrogen play a significant role in the prevention of Alzheimer’s disease?....Pages 227-239
Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule?....Pages 241-252
Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices....Pages 253-263
Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease:a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®....Pages 265-275
Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin®....Pages 277-285
Genomics and dementia — new drug targets ahead?....Pages 287-291
Are β-sheet breaker peptides dissolving the therapeutic problem of Alzheimer’s disease?....Pages 293-301
Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer’s disease — a target for neuroprotective treatment strategies?....Pages 303-307
Pharmacological targets to inhibit alzheimer neurofibrillary degeneration....Pages 309-319
Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology....Pages 321-325
Effects of Cerebrolysin™ on amyloid-β deposition in a transgenic model of Alzheimer’s disease....Pages 327-336
Vitamin E binding protein A famin Protects Neuronal Cells in vitro ....Pages 337-345
Recent developments in the pathology of Parkinson’s disease....Pages 347-384
Back Matter....Pages 384-384